Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmark Diagnostics (GNMK)

Genmark Diagnostics (GNMK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 864,934
  • Shares Outstanding, K 71,071
  • Annual Sales, $ 88,020 K
  • Annual Income, $ -47,350 K
  • 60-Month Beta 3.05
  • Price/Sales 10.23
  • Price/Cash Flow N/A
  • Price/Book 9.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.07
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.60 +21.79%
on 09/04/20
16.05 -19.58%
on 08/19/20
-3.06 (-19.14%)
since 08/18/20
3-Month
10.60 +21.79%
on 09/04/20
20.88 -38.17%
on 08/05/20
+0.60 (+4.87%)
since 06/18/20
52-Week
3.36 +284.23%
on 03/02/20
20.88 -38.17%
on 08/05/20
+7.02 (+119.19%)
since 09/18/19

Most Recent Stories

More News
Are Options Traders Betting on a Big Move in GenMark Diagnostics (GNMK) Stock?

Investors need to pay close attention to GenMark Diagnostics (GNMK) stock based on the movements in the options market lately.

GNMK : 12.72 (+4.52%)
GenMark Diagnostics' ePlex(R) Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens

GNMK : 12.72 (+4.52%)
GenMark Diagnostics' ePlex(R) Respiratory Pathogen Panel 2 (RP2) achieves CE Mark

Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens

GNMK : 12.72 (+4.52%)
Genmark Diagnost Has Returned 21.1% Since SmarTrend Recommendation (GNMK)

SmarTrend identified a Downtrend for Genmark Diagnost (NASDAQ:GNMK) on August 24th, 2020 at $14.66. In approximately 2 weeks, Genmark Diagnost has returned 21.08% as of today's recent price of $11.57....

GNMK : 12.72 (+4.52%)
Cushman & Wakefield Brokers Two Leases with Diagnostics Companies Totaling Over 100,000 SF in San Diego

Cushman & Wakefield (NYSE: CWK) recently announced the firm has brokered two leases comprising over 100,000 square feet (sf) of new occupancy at the NorthPointe and Carlsbad Crossroads projects in Carlsbad...

GNMK : 12.72 (+4.52%)
CWK : 12.11 (-2.02%)
Uptrend Call Working As Genmark Diagnost Stock Rises 30.2% (GNMK)

SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on June 16th, 2020 at $11.76. In approximately 2 months, Genmark Diagnost has returned 30.19% as of today's recent price of $15.31.

GNMK : 12.72 (+4.52%)
GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor(R) SARS-CoV-2 Test

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified the U.S. Food and Drug Administration (FDA) of...

GNMK : 12.72 (+4.52%)
Shares of GNMK Up 35.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Genmark Diagnost (NASDAQ:GNMK) on June 16th, 2020 at $11.76. In approximately 2 months, Genmark Diagnost has returned 35.63% as of today's recent price of $15.95.

GNMK : 12.72 (+4.52%)
Diagnostics Begin to Play a Greater Role in the Fight Against Cancer

, /PRNewswire/ -- The diagnostics industry is highly diverse, with a vast number of testing methods already on the market and a consistent flow of new technologies. In fact, diagnostics are no longer...

NTRA : 60.81 (-0.21%)
DGX : 113.19 (+0.53%)
GNMK : 12.72 (+4.52%)
CEMI : 4.48 (-0.44%)
GenMark Diagnostics Reports Second Quarter 2020 Results

GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020.

GNMK : 12.72 (+4.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GNMK with:

Business Summary

GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic...

See More

Key Turning Points

2nd Resistance Point 13.19
1st Resistance Point 12.68
Last Price 12.72
1st Support Level 11.74
2nd Support Level 11.31

See More

52-Week High 20.88
Fibonacci 61.8% 14.19
Last Price 12.72
Fibonacci 50% 12.12
Fibonacci 38.2% 10.05
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar